These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31355158)

  • 1. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve.
    Fidelman N; Johanson C; Kohi MP; Kolli KP; Kohlbrenner RM; Lehrman ED; Taylor AG; Kelley RK; Yao FY; Roberts JP; Kerlan RK
    J Hepatocell Carcinoma; 2019; 6():93-103. PubMed ID: 31355158
    [No Abstract]   [Full Text] [Related]  

  • 2. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization.
    Wholey M; Palacios Iii R; Wholey D; Mendez A
    Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma.
    Galastri FL; Nasser F; Affonso BB; Valle LGM; Odísio BC; Motta-Leal Filho JM; Salvalaggio PR; Garcia RG; de Almeida MD; Baroni RH; Wolosker N
    World J Hepatol; 2020 Jan; 12(1):21-33. PubMed ID: 31984118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting bead transarterial chemoembolization could improve the hepatic hemodynamics of patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Wang T; Du YN; Sun J; Song H; Jiang Y; Liu F; Lv X
    J Gastrointest Oncol; 2023 Feb; 14(1):302-311. PubMed ID: 36915464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
    Gorodetski B; Chapiro J; Schernthaner R; Duran R; Lin M; Lee H; Lenis D; Stuart EA; Nonyane BA; Pekurovsky V; Tamrazi A; Gebauer B; Schlachter T; Pawlik TM; Geschwind JF
    Eur Radiol; 2017 Feb; 27(2):526-535. PubMed ID: 27277261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
    Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
    Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 14. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Nakano M; Okamura S; Noda Y; Kamachi N; Sakai M; Suzuki H; Nomiyama M; Kuromatsu R; Koga H; Torimura T
    Oncology; 2020; 98(8):558-565. PubMed ID: 32422633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
    Burrel M; Reig M; Forner A; Barrufet M; de Lope CR; Tremosini S; Ayuso C; Llovet JM; Real MI; Bruix J
    J Hepatol; 2012 Jun; 56(6):1330-5. PubMed ID: 22314428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion.
    Nishi M; Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    Hepatol Res; 2018 Mar; 48(4):329-332. PubMed ID: 29098752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.